• 回到顶部
  • 4006560232
  • 微信扫码咨询

BFB

 

人结肠癌细胞HCT-116

 

BLUEFBIO Product Sheet

 

细胞名称

人结肠癌细HCT-116                  

img1

货物编码

BFN60800649

产品规格

T25培养x1

1.5ml冻存x2

细胞数量

1x10^6

1x10^6

保存温度

37

-198

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研用途          2类

 

培养体系

DMEM高糖培养基Hyclone+10%胎牛血清Gibco+1%双抗Hyclone

培养温度

37

二氧化碳浓度

5%

简介

人结肠癌细HCT-116细胞取自男性结肠癌患者。人结肠癌细HCT-116细胞由青旗(上海)生物技术发展有限公司2018年引种ATCC(CCL-247)

注释

Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 3.

Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Part of: NCI-60 cancer cell line panel.

Doubling time: 36 hours (PubMed=25984343); 17.1 hours (PubMed=22628656); 22 hours (PubMed=23546019); 17.4 hours (NCI-DTP); ~25-48 hours (DSMZ); ~21 hours (PBCF).

Microsatellite instability: Instable (MSI-high) (PubMed=9000147; PubMed=10674020; PubMed=23671654; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: HLA class I peptidome analysis by proteomics.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: miRNA expression profiling.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Misspelling: HCT-166; In BTO BTO:0004743, now obsoleted.

Misspelling: HTC 116; Occasionally.

Misspelling: HTC-116; Occasionally.

Misspelling: Htc-116; Occasionally.

Misspelling: HTC116; Occasionally.

Misspelling: HTC1116; Occasionally.

STR信息

Amelogenin: X,Y

CSF1PO: 7,10

D13S317: 10,12

D16S539: 11,13

D5S818: 10,11

D7S820: 11,12

TH01: 8,9

TPOX: 8,9

vWA: 17,22

参考文献

 

 

PubMed=19927377; DOI=10.1002/gcc.20730

Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.

Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Genes Chromosomes Cancer 49:204-223(2010)

 

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192

Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)

 

PubMed=20606684; DOI=10.1038/sj.bjc.6605780

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Br. J. Cancer 103:340-346(2010)

 

PubMed=21912889; DOI=10.1007/s10637-011-9744-z

Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Invest. New Drugs 30:2035-2045(2012)

 

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

 

PubMed=22384151; DOI=10.1371/journal.pone.0032096

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

 

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=22628656; DOI=10.1126/science.1218595

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

 

PubMed=23272949; DOI=10.1186/1755-8794-5-66

Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

BMC Med. Genomics 5:66-66(2012)

 

PubMed=23546019; DOI=10.3892/ijo.2013.1868

Petitprez A., Poindessous V., Ouaret D., Regairaz M., Bastian G., Guerin E., Escargueil A.E., Larsen A.K.

Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

Int. J. Oncol. 42:1644-1653(2013)

 

PubMed=23671654; DOI=10.1371/journal.pone.0063056

Lu Y., Soong T.D., Elemento O.

A novel approach for characterizing microsatellite instability in cancer cells.

PLoS ONE 8:E63056-E63056(2013)

 

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

 

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

 

PubMed=24042735; DOI=10.1038/oncsis.2013.35

Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.

Epigenetic and genetic features of 24 colon cancer cell lines.

Oncogenesis 2:E71-E71(2013)

 

PubMed=24279929; DOI=10.1186/2049-3002-1-20

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20-20(2013)

 

PubMed=23631600; DOI=10.1021/pr400260h

Loftus N.J., Lai L., Wilkinson R.W., Odedra R., Wilson I.D., Barnes A.J.

Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.

J. Proteome Res. 12:2980-2986(2013)

 

PubMed=24670534; DOI=10.1371/journal.pone.0092047

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

 

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)

 

PubMed=25960936; DOI=10.4161/21624011.2014.954893

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:E954893-E954893(2014)

 

PubMed=25984343; DOI=10.1038/sdata.2014.35

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

 

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

 

PubMed=25576301; DOI=10.1074/mcp.M114.042812

Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.

Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.

Mol. Cell. Proteomics 14:658-673(2015)

 

PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019

Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K., Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.

Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines.

J. Proteomics 127:247-258(2015)

 

PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002-7002(2015)

 

PubMed=26169745; DOI=10.1186/s12967-015-0576-z

Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D., Suhre K., Rafii A.

Metabolic signatures differentiate ovarian from colon cancer cell lines.

J. Transl. Med. 13:223-223(2015)

 

PubMed=26537799; DOI=10.1074/mcp.M115.051235

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)illin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)

 

PubMed=27377824; DOI=10.1038/sdata.2016.52

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=27807467; DOI=10.1186/s13100-016-0078-4

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20-20(2016)

 

PubMed=28192450; DOI=10.1371/journal.pone.0171435

Fasterius E., Raso C., Kennedy S., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.

A novel RNA sequencing data analysis method for cell line authentication.

PLoS ONE 12:E0171435-E0171435(2017)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Andersen C.L., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

 

PubMed=28683746; DOI=10.1186/s12943-017-0691-y

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Mol. Cancer 16:116-116(2017)

 

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)

 

PubMed=29101300; DOI=10.15252/msb.20177701

Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.

Pharmacoproteomic characterisation of human colon and rectal cancer.

Mol. Syst. Biol. 13:951-951(2017)

 

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

验收细胞注意事 

1、收到人结肠癌细HCT-116细胞,请查看瓶子是否有破裂,培养基是否漏出,是否浑浊,如有请尽快联系 

2、收到人结肠癌细HCT-116细胞,如包装完好,请在显微镜下观察细胞,由于运输过程中的问题,细胞培养瓶中的贴壁细胞有可能从瓶壁中脱落下来,显微镜下观察会出现细胞悬浮的情况,出现此状态时,请不要打开细胞培养瓶,应立即将培养瓶置于细胞培养箱里静 3-5 小时左右,让细胞先稳定下,再于显微镜下观察,此时多数细胞会重新贴附于瓶壁。如细胞仍不能贴壁,请用台盼蓝染色法鉴定细胞活力,如台盼蓝染色证实细胞活力正常请按悬浮细胞的方法处理 

3、收到人结肠癌细HCT-116细胞后,请镜下观察细胞,用恰当方式处理细胞。若悬浮的细胞较多,请离心收集细胞,接种到一个新的培养瓶中。弃掉原液,使用新鲜配制的培养基,使用进口胎牛血清。刚接到细胞,若细胞不多 血清浓度可以加 15%去培养。若细胞迏 80% ,血清浓度还是 10 

4、收到人结肠癌细HCT-116细胞时如无异常情 ,请在显微镜下观察细胞密度,如为贴壁细胞,未超80%汇合度时,将培养瓶中培养基吸出,留 5-10ML 培养基继续培养:超 80%汇合度时,请按细胞培养条件传代培养。如为悬浮细胞,吸出培养液1000 /分钟离 3 分钟,吸出上清,管底细胞用新鲜培养基悬浮细胞后移回培养瓶 

5、将培养瓶置 37培养箱中培养,盖子微微拧松。吸出的培养基可以保存在灭菌过的瓶子里,存放 4冰箱,以备不时之需 

624 小时后,人结肠癌细HCT-116细胞形态已恢复并贴满瓶壁,即可传代。(贴壁细胞)将培养瓶里的培养基倒去, 3-5ml(以能覆盖细胞生长面为准PBS  Hanks液洗涤后弃去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化时间以具体细胞为准,一 1-3 分钟,不超 5 分钟。可以放37培养箱消化。轻轻晃动瓶壁,见细胞脱落下来,加 3-5ml 培养基终止消化。用移液管轻轻吹打瓶壁上的细胞,使之完全脱落,然后将溶液吸入离心管内离心1000rpm/5min。弃上清,视细胞数量决定分瓶数,一般一传二,如细胞量多可一传三,有些细胞不易传得过稀,有些生长较快的细胞则可以多传几瓶,以具体细胞和经验为准。(悬浮细胞)用移液管轻轻吹打瓶壁,直接将溶液吸入离心管离心即可 

7、贴壁细 ,悬浮细胞。严格无菌操作。换液时,换新的细胞培养瓶和换新鲜的培养液375%CO2 培养。

 

特别提醒 原瓶中培养基不宜继续使用,请更换新鲜培养基培养。

 

浏览量:0